4-Aninomethylbicyclo[2.2.2]-Octane-1-Carboxylic Acid a New Potent Antifibrinolytic Agent

W Baumgarten; L. I Priester; D. W Stiller; A. E. W Duncan; J. L Ciminera; L. J Loeffler

doi:10.1055/s-0038-1651352

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1969; 22(02): 263-272
DOI: 10.1055/s-0038-1651352

Originalarbeiten-Original Articles-Travaux Originaux

Schattauer GmbH

4-Aninomethylbicyclo[2.2.2]-Octane-1-Carboxylic Acid a New Potent Antifibrinolytic Agent

Its Evaluation by In Vitro Assay Procedures

W Baumgarten

¹Medicinal Chemistry Department, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania

,

L. I Priester

¹Medicinal Chemistry Department, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania

,

D. W Stiller

¹Medicinal Chemistry Department, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania

,

A. E. W Duncan

¹Medicinal Chemistry Department, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania

,

J. L Ciminera

¹Medicinal Chemistry Department, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania

,

L. J Loeffler

¹Medicinal Chemistry Department, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania

› Author Affiliations

Abstract

Summary

In this publication we describe a new antifibrinolytic compound, 4-aminomethyl-bicyclo[2.2.2]-octane-l-carboxylic acid. This compound is the most active antifibrinolytic agent known up to the present.

Its activity has been characterized by two in vitro assay procedures and its relative potency compared to the standard antifibrinolytic agent, ε-aminocaproic acid.

Two assay procedures for the evaluation of antifibrinolytic compounds have been developed with particular emphasis on the capability to yield statistically valid results.

Full Text

References

References
1 Special issue on the studies concerning the action of epsilon-amino-N-caproic acid. Keio J. Med. 8: 211-344 1959;
2 Dubber A. H. C, McNicol G. P, Douglas A. S, Melander B. Some properties of the anti-fibrinolytically active isomer of aminomethylcyclohexane carboxylic acid. Lancet II: 1317 1964;
3 Dubber A. H. G, McNicol G. P, Douglas A. S. Aminomethylcyclohexane carboxylic acid (AMCHA) a new synthetic fibrinolytic inhibitor. Brit. J. Haemat. 11: 237 1965;
4 Melander B, Granstrand G. B, Hanshoff G. Biochemistry and toxicology of amikapron (R), the antifibrinolytically active isomer of AMCHA (A comparative study with ε-aminocaproic acid). Acta pharmacol. (Kbh.) 22: 340 1965;
5 Markwardt E. F, Haustein K. O, Klocking H. P. Pharmacological characterization of a new antifibrinolytic agent, p-aminomethylbenzoic acid. Arch. int. Pharmacodyn. 152: 233 1964;
6 Baumgarten W. Synthetic antifibrinolytic agents, their chemistry and biochemistiy. Chemical control of fibrinolysis. Wiley 1969.
7 Loejfler L. J, Britcher S. F, Baumgarten W. Bridged Bicyclic and Polycyclic amino acids. Potent new inhibitors of the fibrinolytic process. Preliminary Report presented at the American Chemical Society Meeting, Medicinal Section New York City Sept. 7-12, 1969.
8 Wasserman A. E, Giminera J. L, Hayflick L, Verwey W. F. The quantitative determination of streptokinase. J. Lab. clin. Med. 41: 812 1953;
9 Baumgarten W, Giminera J. L, Gole R. B. Assay procedure for the quantitative determination of clot lysis activity. Vox Sang. 5: 416 1960;
10 Baumgarten TT, Date S, Priester L, Giminera J. L, Richard M. Antagonists of fibrinolytic activity. Fed. Proc. 25: 498 1966;
11 von Kaulla K. N. Structure-dependent fibrinolytic (clot dissolving) activity of antiinflammatory drugs and related compounds. Arzneimittel-Forsch. 18: 407 1968;
12 Baumgarten W, Stiller D. W. Non-enzymatic fibrinolysis. A possible explanation of the mechanism by which fibrinolysis is achieved. Abstracts, XII Congress International Society of Hematology, New York. 186 UU 4, Sept. (1968).
13 Finney D. J. Statistical method in biological assay. 99-117. Hafner Publishing Company; New York: 1952
14 Skoza L, Tse A. O, Semar M, Johnson A. J. Comparative activities of amino and polypeptide inhibitors on natural and synthetic substrates. Ann. N. Y. Acad. Sci. 146: 659 1968;
15 Landmann H. Vergleichende Untersuchungen über Antifibrinolytika. Folia haemat. 87: 106 1967;
16 Okamoto S, Oshiba S, Mihara H, Okamoto U. Synthetic inhibitors of fibrinolysis: in vitro and in vivo mode of action. Ann. N. Y. Acad. Sci. 146: 414 1968;
17 Iwamoto M, Abiko Y, Shimizu M. Plasminogen-plasmin system III. Kinetics of plasminogen activation and inhibition by some synthetic inhibitors. J. Biochem. (Tokyo) 64: 759 1968;
18 Shimizu M, Aoyagi T, Iwamoto M, Abiko Y, Naito T, Okano A. Medicinal chemical studies on antiplasmin drugs I. Establishment of the screening assay method for antiplasmin drugs and the superiority of trans-4-aminomethylcyclohexane carboxylic acid (Transexamic acid) to the cis-form. Chem. pharm. Bull. 16: 357 1968;